These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24970929)

  • 21. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis.
    Moore DC; Arnall JR
    Ann Pharmacother; 2023 Aug; 57(8):970-977. PubMed ID: 36476151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cold agglutinins: fending off the attack.
    Berentsen S
    Blood; 2019 Feb; 133(9):885-886. PubMed ID: 30819775
    [No Abstract]   [Full Text] [Related]  

  • 23. Complement activation by cold agglutinins.
    Kirschfink M; Fritze H; Roelcke D
    Vox Sang; 1992; 63(3):220-6. PubMed ID: 1448966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic peptide inhibitors of complement serine proteases--II. Effects on hemolytic activity and production of C3a and C4a.
    Schasteen CS; McLafferty SA; Glover GI; Han CY; Mayden JC; Liu WS; Levine RP
    Mol Immunol; 1988 Dec; 25(12):1269-75. PubMed ID: 3266292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma.
    Bauduer F
    Br J Haematol; 2001 Mar; 112(4):1085-6. PubMed ID: 11324638
    [No Abstract]   [Full Text] [Related]  

  • 26. C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.
    Adesanya TMA; Campbell CM; Cheng L; Ogbogu PU; Kahwash R
    J Clin Immunol; 2021 May; 41(4):729-732. PubMed ID: 33474624
    [No Abstract]   [Full Text] [Related]  

  • 27. [Cold agglutinin disease -  no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].
    Adam Z; Pejchalová A; Chlupová G; Ríhová L; Pour L; Krejčí M; Cervinek L; Král Z; Mayer J
    Vnitr Lek; 2013 Sep; 59(9):828-40. PubMed ID: 24073955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Structural Basis for Complement Inhibition by Gigastasin, a Protease Inhibitor from the Giant Amazon Leech.
    Pang SS; Wijeyewickrema LC; Hor L; Tan S; Lameignere E; Conway EM; Blom AM; Mohlin FC; Liu X; Payne RJ; Whisstock JC; Pike RN
    J Immunol; 2017 Dec; 199(11):3883-3891. PubMed ID: 29061764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions.
    Gál P; Dobó J; Závodszky P; Sim RB
    Mol Immunol; 2009 Sep; 46(14):2745-52. PubMed ID: 19477526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. alpha 2-Macroglobulin binds to and inhibits mannose-binding protein-associated serine protease.
    Terai I; Kobayashi K; Matsushita M; Fujita T; Matsuno K
    Int Immunol; 1995 Oct; 7(10):1579-84. PubMed ID: 8562502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacity of rituximab in hemolytic anemia with cold autoantibodies case].
    Sekkach Y; Hammi S; Elqatni M; Fatihi J; Elomri N; Mekouar F; Badaoui M; Jira M; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
    Ann Pharm Fr; 2011 Jul; 69(4):205-8. PubMed ID: 21840439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation.
    Matsushita M; Fujita T
    Immunobiology; 1995 Nov; 194(4-5):443-48. PubMed ID: 8749236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a catalytic exosite for complement component C4 on the serine protease domain of C1s.
    Duncan RC; Mohlin F; Taleski D; Coetzer TH; Huntington JA; Payne RJ; Blom AM; Pike RN; Wijeyewickrema LC
    J Immunol; 2012 Sep; 189(5):2365-73. PubMed ID: 22855709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
    Röth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Weitz IC; Yoo R; Jayawardene D; Vagge DS; Kralova K; Shafer F; Wardȩcki M; Lee M; Berentsen S
    Am J Hematol; 2023 Aug; 98(8):1246-1253. PubMed ID: 37246953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoimmune hemolytic anemia.
    Hill A; Hill QA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):382-389. PubMed ID: 30504336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic hemolytic anemia due to cold agglutinins. II. The role of C' in red cell destruction.
    Evans RS; Turner E; Bingham M; Woods R
    J Clin Invest; 1968 Apr; 47(4):691-701. PubMed ID: 5641611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia].
    Ono K; Sato T; Iyama S; Tatekoshi A; Hashimoto A; Kamihara Y; Horiguchi H; Kikuchi S; Takada K; Hayashi T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
    Rinsho Ketsueki; 2013 Nov; 54(11):2053-5. PubMed ID: 24305538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of C1 by soluble IgG aggregates as detected by a novel one-step hemolytic assay that specifically measures the proenzyme form of C1s.
    Doekes G; van Es LA; Daha MR
    J Immunol; 1983 Oct; 131(4):1924-9. PubMed ID: 6604753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remission of severe cold agglutinin disease after Rituximab therapy.
    Layios N; Van Den Neste E; Jost E; Deneys V; Scheiff JM; Ferrant A
    Leukemia; 2001 Jan; 15(1):187-8. PubMed ID: 11243390
    [No Abstract]   [Full Text] [Related]  

  • 40. Immune complex independent activation of complement, C1s secreted from hamster embryo malignant fibroblasts, Nil2C2 in serum free culture medium.
    Yamaguchi K; Kato N; Sakai N; Matsumoto M; Nagasawa S; Hatsuse H; Toyoguchi T; Moriya H; Sakiyama H
    Biochim Biophys Acta; 1994 Mar; 1205(1):133-8. PubMed ID: 8142477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.